Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway.
about
Less Is More: Substrate Reduction Therapy for Lysosomal Storage DisordersMorquio A syndrome: diagnosis and current and future therapiesNewborn screening and diagnosis of mucopolysaccharidosesInhibitory peptides of the sulfotransferase domain of the heparan sulfate enzyme, N-deacetylase-N-sulfotransferase-1.Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type IIThe phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activationTherapeutic approaches for lysosomal storage diseasesImpairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease.Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids.Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse ModelActivities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids.Synthetic genistein derivatives as modulators of glycosaminoglycan storage.A genetic model of substrate reduction therapy for mucopolysaccharidosis.Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patientsA systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfaseNonsteroidal anti-inflammatory drugs modulate cellular glycosaminoglycan synthesis by affecting EGFR and PI3K signaling pathwaysGene expression-targeted isoflavone therapy.Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.Lysosomal storage diseases--the horizon expands.Current and potential therapeutic strategies for mucopolysaccharidoses.Treatment of lysosomal storage disorders: successes and challenges.Signal transduction in inherited metabolic disorders: a model for a possible pathogenetic mechanism.Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.Small molecules as therapeutic agents for inborn errors of metabolism.How close are we to therapies for Sanfilippo disease?Correction of Huntington's Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model.
P2860
Q26744230-0241C755-D90A-45E4-B0D0-9688D75F111EQ27014063-7BFC9B73-8254-4546-8606-D7F87DF9B1C6Q27025080-E37FD2B8-E8B6-4419-96E5-37A2D7C873A4Q33529358-5670DECB-9183-4367-A251-37D4AD15738FQ33730608-F9D46976-73D2-4015-B773-39EDAE2717C9Q33761283-C45B8CBA-4DC0-4368-AE44-712BB7D3D12FQ34311420-E5C8C64C-40AE-4276-A7A6-B4D0928A1698Q34610922-90066FF5-86F2-4F6B-80E2-2293D8EE8D32Q34626878-A972A6C3-AFB2-47FF-903C-DC5B49163762Q34757062-24AAB3C3-4025-4C2E-98A3-3FD40B71FC4BQ35206289-FA079040-D4EB-41C5-81DF-918FBA7AF685Q35795405-257642D7-D548-478A-9DDD-3866380A7160Q36030017-27C579DF-EADE-47E1-AE15-9799F52E0F2DQ36232973-76A7D724-170C-430D-A50E-F28C5FDCC076Q36332885-8D7C4737-9775-4432-904B-6DCED7501BCEQ36516376-8476BE49-4AE9-49B2-AE76-5B4C7E52799EQ37390462-66E1CF09-3376-4D09-9BD3-4BEC33EB931EQ37667936-D1DA4D1F-FAAC-4A66-88A9-3D376DBC0780Q37987877-D4BDFEA1-1049-4953-93D6-D4338E3D6A6DQ38040710-6DA79BAD-B1B7-44FD-AB78-BB3958B6D5DBQ38128478-B2114C6B-0B00-4804-901A-DB9554658CAEQ38194635-D962DB5A-0163-4362-9069-05EBCF5014A2Q38211269-42995912-2D4A-4A27-AA45-AFB01C8BB56FQ38367296-C32D30DF-3807-40BA-9F0A-B33E3A2EA59FQ39008165-81FCC228-B23C-43DA-8CA2-93AD07F44FDCQ39038060-112C979C-2FB8-4054-A030-3BCFD9D09D6DQ45872078-760F72BD-C5AA-4CFA-A406-C8F0202431D8Q50050416-C556153D-F335-41E3-8C2A-77BD7939553B
P2860
Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@ast
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@en
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@nl
type
label
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@ast
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@en
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@nl
prefLabel
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@ast
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@en
Genistein-mediated inhibition ...... owth factor-dependent pathway.
@nl
P2860
P50
P356
P1476
Genistein-mediated inhibition ...... rowth factor-dependent pathway
@en
P2860
P2888
P356
10.1186/1423-0127-16-26
P577
2009-03-02T00:00:00Z